IMMUNIC (IMUX) Director Robert T. Nagel Receives Award

What Happened
Robert Thorvald Nagel, a director of IMMUNIC, Inc. (IMUX), was granted a derivative equity award for 25,370 shares on 2026-09-16. The award is reported at $0.00 (total reported value $0) and is classified on the Form 4 as an "A" (grant/award). The award vests in monthly increments over one year.

Key Details

• Transaction date: 2026-09-16; Form 4 filed: 2026-09-18 (timely filing).
• Security: derivative equity award of 25,370 shares; reported price $0.00; total reported value $0.
• Vesting: monthly vesting over one year (footnote F1).
• Beneficial ownership: Reporting person is a member of BVF Partners L.P. and is obligated to transfer any economic benefit from the shares to BVF; he disclaims beneficial ownership except to any pecuniary interest (footnote F2).
• Shares owned following the transaction: not specified in the filing.
• Transaction code: A = Award/Grant (not a purchase or sale).

Context
This was an equity grant (derivative award) rather than an open-market purchase or sale. Derivative awards (e.g., RSUs or options) typically vest over time—here monthly over a year—so these shares are not immediately available for sale. Because the reported economic benefit is contractually assigned to BVF, this filing reflects institutional interests rather than a personal investment decision by the director.